SpyGlass Pharma Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Patrick Mooney
Chief executive officer
US$3.3m
Total compensation
| CEO salary percentage | 13.38% |
| CEO tenure | 5yrs |
| CEO ownership | 0.5% |
| Management average tenure | 3.1yrs |
| Board average tenure | 2.8yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$45m |
| Dec 31 2025 | US$3m | US$445k | -US$40m |
| Sep 30 2025 | n/a | n/a | -US$36m |
| Dec 31 2024 | US$1m | US$417k | -US$29m |
Compensation vs Market: Patrick's total compensation ($USD3.32M) is about average for companies of similar size in the US market ($USD3.54M).
Compensation vs Earnings: Patrick's compensation has increased whilst the company is unprofitable.
CEO
Patrick Mooney (52 yo)
Mr. Patrick H. Mooney serves as CEO and Director at SpyGlass Ophthalmics, Inc since July 2021. He serves as Chief Executive Officer and Director at SpyGlassPharma, Inc. Mr. Mooney is responsible for the ov...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.5yrs | US$2.48m | 2.61% $ 16.7m | |
| CEO & Director | 5yrs | US$3.32m | 0.55% $ 3.5m | |
| Chief Research & Development Officer | 1.4yrs | US$1.57m | 0% $ 0 | |
| Co-founder & Chief Technology Advisor | 7.5yrs | no data | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Chief Operating Officer | 4.8yrs | no data | 0.29% $ 1.8m | |
| General Counsel | less than a year | no data | no data | |
| Vice President of Human Resources | no data | no data | no data | |
| Senior Vice President of Clinical Development | no data | no data | no data | |
| Senior Vice President | no data | no data | no data | |
| VP & Head of Clinical Operations | no data | no data | no data | |
| VP & Head of Commercial | less than a year | no data | no data |
Experienced Management: SGP's management team is considered experienced (3.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 7.5yrs | US$2.48m | 2.61% $ 16.7m | |
| CEO & Director | 5yrs | US$3.32m | 0.55% $ 3.5m | |
| Independent Director | 1.2yrs | no data | no data | |
| Independent Director | less than a year | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$296.01k | 0.83% $ 5.3m | |
| Independent Director | 3yrs | no data | no data | |
| Independent Director | 7.2yrs | no data | no data | |
| Independent Director | 1yr | no data | no data | |
| Member of Medical Advisory Board | no data | no data | no data | |
| Independent Director | less than a year | US$414.73k | no data | |
| Member of Medical Advisory Board | no data | no data | no data |
Experienced Board: SGP's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/07/06 13:13 |
| End of Day Share Price | 2026/07/06 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SpyGlass Pharma, Inc. is covered by 5 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Yigal Nochomovitz | Citigroup Inc |
| Yi Chen | H.C. Wainwright & Co. |
| Yuchen Ding | Jefferies LLC |